95093-95-1

Basic information

• Product Name: (S)-(+)-4-(2,3-EPOXYPROPOXY)CARBAZOLE
• Synonyms: (S)-4-(2-OxiranylMethoxy)carbazole;(S)-4-(OxiranylMethoxy)-9H-carbazole;4-(((2S)-Oxiranyl)Methoxy)-9H-carbazole;4-[(2S)-2-OxiranylMethoxy]-9H-carbazole;(S)-(+)-4-(2,3-EPOXYPROPOXY)CARBAZOLE;4-((S)-1-OXIRANYLMETHOXY)-9H-CARBAZOLE;(S)-4-(2,3-Epoxypropoxy)-9H-carbazole;(S)-4-(oxiran-2-ylmethoxy)-9H-carbazole(WXG00072)
• CAS NO: 95093-95-1
• Molecular Formula: C₁₅H₁₃NO₂
• Molecular Weight: 239.27
• Product Categories: Aromatics;Chiral Reagents;Aromatics Compounds
• Mol File: 95093-95-1.mol
• Article Data: 12

Chemical Properties

• Melting Point: 158-160°C
• Boiling Point: 464.9°C at 760 mmHg
• Flash Point: 166.4°C
• Appearance: /
• Density: 1.327g/cm³
• Vapor Pressure: 2.23E-08mmHg at 25°C
• Refractive Index: 1.729
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated), Pyridine (Slightly)
• CAS DataBase Reference: (S)-(+)-4-(2,3-EPOXYPROPOXY)CARBAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(+)-4-(2,3-EPOXYPROPOXY)CARBAZOLE(95093-95-1)
• EPA Substance Registry System: (S)-(+)-4-(2,3-EPOXYPROPOXY)CARBAZOLE(95093-95-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 95093-95-1(Hazardous Substances Data)

Usage

Uses

(S)-(+)-4-(2,3-Epoxypropoxy)carbazole (cas# 95093-95-1) is a compound useful in organic synthesis.

InChI:InChI=1/C15H13NO2/c1-2-5-12-11(4-1)15-13(16-12)6-3-7-14(15)18-9-10-8-17-10/h1-7,10,16H,8-9H2/t10-/m0/s1

Upstream product

• 52602-39-8 9H-carbazol-4-ol 
• 115314-14-2 (2s)-(+)-glycidyl 3-nitrobenzenesulfonate 
• 591-20-8 3-Bromophenol 
• 51594-55-9 (R)-(-)-epichlorohydrin 

Downstream Products

• 937193-81-2 (S)-6-[4-[2-[3-(9H-carbazol-4-yloxy)-2-hydroxypropylamino]-2-methylpropyl]phenoxy]-3-iodopyridine 
• 784122-27-6 (S)-6-[4-[2-[3-(9H-carbazol-4-yloxy)-2-hydroxypropylamino]-2-methylpropyl]phenoxy]-3-cyanopyridine 
• 391901-60-3 tert-butyl 4-aminophenethyl[(2 S)-3-(9 H-carbazol-4-yloxy)-2-hydroxypropyl]carbamate 
• 391901-61-4 tert-butyl (2 S)-3-(9 H-carbazol-4-yloxy)-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamate 
• 392690-75-4 (+)-(S)-1-bromo-4-(oxiran-2-ylmethoxy)carbazole 
• 78859-34-4 NSC 305336 
• 95094-00-1 (-)-Carvedilol 
• 143412-40-2 1-amino-3-(9H-carbazol-4-yloxy)-propan-2-ol 
• 1160961-98-7 (S)-4'-(2-{[2-hydroxy-3-(carbazol-4-yloxy)propyl]-amino}ethyl)-2-(2-pyridyl)acetanilide hydrochloride 

Relevant articles and documents

Hybridization of β-Adrenergic Agonists and Antagonists Confers G Protein Bias

Starting from the β-adrenoceptor agonist isoprenaline and beta-blocker carvedilol, we designed and synthesized three different chemotypes of agonist/antagonist hybrids. Investigations of ligand-mediated receptor activation using bioluminescence resonance energy transfer biosensors revealed a predominant effect of the aromatic head group on the intrinsic activity of our ligands, as ligands with a carvedilol head group were devoid of agonistic activity. Ligands composed of a catechol head group and an antagonist-like oxypropylene spacer possess significant intrinsic activity for the activation of Gαs, while they only show weak or even no β-arrestin-2 recruitment at both β1- and β2-AR. Molecular dynamics simulations suggest that the difference in G protein efficacy and β-arrestin recruitment of the hybrid (S)-22, the full agonist epinephrine, and the β2-selective, G protein-biased partial agonist salmeterol depends on specific hydrogen bonding between Ser5.46 and Asn6.55, and the aromatic head group of the ligands.

BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY

The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of the beta-3 adrenergic receptor as medicaments.

NOVEL HETEROCYCLIC COMPOUNDS AS PSTAT3/IL-6 INHIBITORS

The present invention relates to novel heterocyclic compounds of the general formula (I), as IL-6 inhibitors, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly provides novel heterocyclic compounds of the general formula (I). Also included is a method for treatment of cancer, cancer cachexia and inflammatory diseases including immunological diseases, particularly those mediated by cytokines such as IL-6, through pSTAT3 inhibition, in a mammal comprising administering an effective amount of a compound of formula (I) as described above.